CAR T-Cell Therapy Cost

CAR T-cells therapy can be costly as it cost between $370,000 and $1,000,000 to undergo the treatment process. The treatment fess is not inclusive of institution fees and drugs to treat side effects. The CAR T-cells therapy is estimated to cost higher when you factor the hospital time and care for severe reactions. Thus, CAR T-cell therapy is an expensive medical treatment procedure.

CAR T-Cell Therapy Insurance Cover

The treatment plan has many health insurance plans covering CART T-cell, although other institutions do not. Besides, the insurance companies pay a limited amount of money. However, Medicare and Medicaid cover CAR T-cell therapy in specific states. Furthermore, even if your insurance covers your treatment, you have to pay the expenses that are not covered.

Car T-cell Therapy Cost Solutions

So, is there a solution to the costly procedure? Yes, there is a way to minimize the costs associated with the CAR T-cells therapy. The patient could seek treatment in countries producing the drugs needed for the procedure. For instance, the CAR T-cell therapy done in India costs around $30,000 to $ 40,000 per treatment which is the one tenth of similar commercial products. Moreover, an individual can:

Take advantage of numerous resources that assist to minimize the personal expenses.

Partner with a social worker, hospital financial analysist and case manager. The professionals in these areas can assist you plan and strategize the financial process.   

Another affordable plan is to converse with the drug producer and ask if they can help waver some expenses.

Another method to reduce the costs is to carry out the therapies in the medical facilities where they are implemented. Here is a fact, although the cancer facilities are involved in collecting T cells from the patient the institution is not the stakeholder producing the CAR T-cells therapies themselves. The cancer centers ship the medication to pharma corporations which are specialized facilities for engineering and growing of cells. Hence, producing the therapies in house could help promote a point-of-care manufacturing and can help save money and reduce the waiting time.

The Long-term Plan

The future for CAR-T cells is promising beyond blood cancers. The research field in relation to CAR T-cells reported positive results in its trial stages. The patients being testes showed a positive result for tumors, heart disease and HIV infection. Moreover, as the number of individuals eligible for treatments increases the pressure to decrease the cost will likewise reduce.

PHOTO CREDIT:GOOGLE.COM 

WRITTEN BY: AMEDICC.COM